Prostate Cancer

Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.

The combination of olaparib and pembrolizumab continued to demonstrate antitumor activity in patients with metastatic castration-resistant prostate cancer who previously received docetaxel.

Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.

Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies may impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.

Relugolix failed to significantly delay onset of castration resistance compared with standard of care leuprolide in men with advanced prostate cancer.

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

Ashutosh K. Tewari, MD, discusses the benefits of robotic radical prostatectom​y in prostate cancer.

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

Obese men with metastatic castration-resistant prostate cancer have better disease-specific and overall survival than overweight or normal weight patients.

The United Kingdom’s National Institute of Health and Care Excellence has recommended apalutamide for use in combination with androgen deprivation therapy in patients with high-risk hormone-relapsed nonmetastatic prostate cancer and in those with hormone-sensitive metastatic prostate cancer if docetaxel is not suitable or cannot be tolerated.

Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.

The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

During the height of the COVID-19 pandemic, Black patients were significantly less likely to undergo prostate cancer surgery compared with White patients, highlighting potential systemic inequities in care across medical specialties, and providing further rationale to recognize and the unintended diversion in cancer care due to the pandemic.

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

Six-months of adjuvant androgen suppression plus 74 Gy or 78 Gy of concurrent external-beam radiation led to a statistically significant improvement in event-free survival and disease-free survival but failed to improve distant metastasis-free survival and overall survival vs external-beam radiation alone in patients with intermediate-risk prostate cancer.